share_log

HC Wainwright & Co. Maintains Buy on Bellerophon Therapeutics, Lowers Price Target to $2

Benzinga ·  Jun 6, 2023 06:35

HC Wainwright & Co. analyst Andrew Fein maintains Bellerophon Therapeutics (NASDAQ:BLPH) with a Buy and lowers the price target from $30 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment